MX2013000072A - Metodo para producir proteinas autologas. - Google Patents

Metodo para producir proteinas autologas.

Info

Publication number
MX2013000072A
MX2013000072A MX2013000072A MX2013000072A MX2013000072A MX 2013000072 A MX2013000072 A MX 2013000072A MX 2013000072 A MX2013000072 A MX 2013000072A MX 2013000072 A MX2013000072 A MX 2013000072A MX 2013000072 A MX2013000072 A MX 2013000072A
Authority
MX
Mexico
Prior art keywords
gold particles
gelsolin
enrichment
blood samples
container
Prior art date
Application number
MX2013000072A
Other languages
English (en)
Other versions
MX353734B (es
Inventor
Ulrich Schneider
Original Assignee
Arthrogen Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrogen Gmbh filed Critical Arthrogen Gmbh
Publication of MX2013000072A publication Critical patent/MX2013000072A/es
Publication of MX353734B publication Critical patent/MX353734B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)

Abstract

La invención se relaciona a un método para producir al menos una proteína terapéuticamente activa o mezclas de proteína en un contenedor. En el método, el contenedor se llena con un fluido corporal y partículas de oro y se incuba y se forma la proteína terapéuticamente activa en el fluido corporal.
MX2013000072A 2010-07-07 2011-06-21 Metodo para producir proteinas autologas. MX353734B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010026500A DE102010026500A1 (de) 2010-07-07 2010-07-07 Verfahren zur Herstellung von autologen Proteinen
PCT/DE2011/001322 WO2012010128A2 (de) 2010-07-07 2011-06-21 Verfahren zur herstellung von autologen proteinen

Publications (2)

Publication Number Publication Date
MX2013000072A true MX2013000072A (es) 2013-05-17
MX353734B MX353734B (es) 2018-01-26

Family

ID=44735759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000072A MX353734B (es) 2010-07-07 2011-06-21 Metodo para producir proteinas autologas.

Country Status (13)

Country Link
US (1) US9200050B2 (es)
EP (1) EP2590659B1 (es)
JP (1) JP6094761B2 (es)
KR (1) KR20130139837A (es)
CN (1) CN103037873A (es)
AU (1) AU2011282056B2 (es)
BR (1) BR112012033476A2 (es)
CA (1) CA2803941A1 (es)
DE (1) DE102010026500A1 (es)
ES (1) ES2658269T3 (es)
MX (1) MX353734B (es)
RU (1) RU2013104404A (es)
WO (1) WO2012010128A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190218261A1 (en) 2016-09-13 2019-07-18 The Jackson Laboratory Targeted enhanced dna demethylation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301174C (en) * 1997-08-16 2007-11-27 Orthogen Gentechnologie Gmbh A method for inducing therapeutically-effective proteins
US20030108612A1 (en) * 2001-10-31 2003-06-12 Xu Xiaohong Nancy Metallic nanoparticles for inhibition of bacterium growth
PT2002258T (pt) * 2006-03-15 2017-12-18 The Brigham And Women`S Hospital Inc Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas
EP2001496B1 (en) * 2006-03-15 2017-05-31 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases

Also Published As

Publication number Publication date
US20130323200A1 (en) 2013-12-05
AU2011282056A1 (en) 2013-01-24
CN103037873A (zh) 2013-04-10
CA2803941A1 (en) 2012-01-26
AU2011282056B2 (en) 2015-02-26
JP2013537516A (ja) 2013-10-03
RU2013104404A (ru) 2014-08-20
ES2658269T3 (es) 2018-03-09
EP2590659B1 (de) 2017-11-08
WO2012010128A3 (de) 2012-05-31
BR112012033476A2 (pt) 2016-10-25
WO2012010128A2 (de) 2012-01-26
KR20130139837A (ko) 2013-12-23
JP6094761B2 (ja) 2017-03-15
MX353734B (es) 2018-01-26
US9200050B2 (en) 2015-12-01
EP2590659A2 (de) 2013-05-15
DE102010026500A1 (de) 2012-01-12

Similar Documents

Publication Publication Date Title
EP4509189A3 (en) Anti-fcrn antibodies
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1256130A1 (zh) 用於嵌合抗原受体和其他受体的表达的t细胞
MY184914A (en) Methods of administering pirfenidone theraphy
WO2011143511A3 (en) Methods for producing enteroendocrine cells that make and secrete insulin
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2012120344A3 (en) Fracturable container
WO2013025446A3 (en) Anti-fzd10 monoclonal antibodies and methods for their use
WO2012145238A3 (en) Methods for reducing an adverse immune response to a foreign antigen in human using cd4-binding molecules
NZ600079A (en) A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2014028668A3 (en) Stem cell enhancing therapeutics
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
NZ594950A (en) Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
EP2499242A4 (en) METHOD FOR INCREASING THE PERFORMANCE AND IMMOVINATION OF STEM CELLS, INCLUDING IDENTIFICATION OF SPECIFIC PROSTAGLANDIN E2 RECEPTORS
UA112747C2 (uk) Лікарський засіб і спосіб профілактики інфікування віл, профілактики і лікування захворювань, що викликаються віл або асоційовані з віл, у тому числі сніду
NZ701408A (en) Proteins that bind pi16 and uses thereof
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
WO2012122334A3 (en) Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
TWD155282S (zh) 瓶子
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
MX2013000072A (es) Metodo para producir proteinas autologas.
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін
MX350689B (es) Proteinas env lentivirales mutadas y su uso como farmacos.
Springhorn Isolation of human capillary endothelial cells using paramagnetic beads conjugated to anti-PECAM antibodies

Legal Events

Date Code Title Description
FG Grant or registration